144 related articles for article (PubMed ID: 17644742)
21. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients.
Rocino A; de Biasi R
Vox Sang; 1999; 77 Suppl 1():65-9. PubMed ID: 10529692
[TBL] [Abstract][Full Text] [Related]
22. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Oldenburg J; Lacroix-Desmazes S; Lillicrap D
Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. A study of the cooperative group of hemophilia.
Ambriz-Fernández R; Reyna-Fregoso MP; Pizzuto-Chávez J; Rodríguez-Moyado H; Farfán-Canto JM; Trueba-Christy E; Collazo-Jaloma J
Arch Invest Med (Mex); 1985; 16(3):225-35. PubMed ID: 3938639
[No Abstract] [Full Text] [Related]
24. Factor VIII/von Willebrand factor.
Zimmerman TS; Ruggeri ZM; Fulcher CA
Prog Hematol; 1983; 13():279-309. PubMed ID: 6422506
[No Abstract] [Full Text] [Related]
25. Allergenic vaccines administration and inhibitor development in haemophilia.
Bermejo N; Martín Aguilera C; Carnicero F; Bergua J
Haemophilia; 2012 Sep; 18(5):e392-3. PubMed ID: 22672147
[No Abstract] [Full Text] [Related]
26. von Willebrand factor: what is its role in the immune response in haemophilia?
Kaveri S; Mannucci PM; Kurth MH; Ewing N; Kessler CM; Nugent DJ; Gomperts ED
Haemophilia; 2011 Jan; 17(1):e235-8. PubMed ID: 20546026
[No Abstract] [Full Text] [Related]
27. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
Warrier AI; Lusher JM
J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
[TBL] [Abstract][Full Text] [Related]
28. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
Franchini M; Tagliaferri A; Mengoli C; Cruciani M
Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
[TBL] [Abstract][Full Text] [Related]
30. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
Klukowska A; Komrska V; Jansen M; Laguna P
Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
[TBL] [Abstract][Full Text] [Related]
31. Recent improvements in the clinical treatment of coagulation factor inhibitors.
Franchini M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
[TBL] [Abstract][Full Text] [Related]
32. Inhibitor development in patients with hemophilia: an overview.
Leissinger CA
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
[No Abstract] [Full Text] [Related]
33. Factor VIII related activities in concentrates.
Nilsson IM; Borge L; Gunnarsson M; Kristoffersson AC
Scand J Haematol Suppl; 1984; 41():157-72. PubMed ID: 6440282
[No Abstract] [Full Text] [Related]
34. Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A.
Labarque V; Perinparajah V; Bouskill V; Stain AM; Wakefield C; Manuel C; Blanchette VS; James PD; Lillicrap D; Carcao MD
Am J Hematol; 2017 Jun; 92(6):E94-E96. PubMed ID: 28249352
[No Abstract] [Full Text] [Related]
35. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
36. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
Wu RH; Wei QQ
Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
[No Abstract] [Full Text] [Related]
37. Management of bleeding disorders: basic science.
Ofosu FA; Santagostino E; Grancha S; Marco P
Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
[TBL] [Abstract][Full Text] [Related]
38. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
[TBL] [Abstract][Full Text] [Related]
39. Response to the letter to the editor by Ewenstein BM and Reininger AJ.
Klukowska A; Komrska V; Jansen M; Laguna P
Haemophilia; 2013 Jul; 19(4):e257-8. PubMed ID: 23600976
[No Abstract] [Full Text] [Related]
40. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
